Varenicline and Antiretroviral Therapy in Patients With HIV

Tornero, Carlos; Mafe, Carmen

doi:10.1097/qai.0b013e3181ba1beb

Cited by 22 publications

(19 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…64 Some patients discontinued the trial because of poor motivation (three patients) or adverse effects of varenicline (one patient). Only the first 15 days of varenicline was free to patients, and the authors noted that a majority of patients did not complete treatment because of medication cost.…”

Section: Medication Treatmentsmentioning

confidence: 99%

Smoking Cessation for People Living With HIV/AIDS: A Literature Review and Synthesis

Ledgerwood

Yskes

2016

NICTOB

View full text Add to dashboard Cite

Introduction: People living with HIV/AIDS (PLWHA) are more likely to smoke cigarettes than are individuals in the general population. The health implications of tobacco use are substantially more dire among PLWHA than among otherwise healthy smokers, including higher rates of various cancers, cardiovascular disease, inflammation, and lung infections. Efficacious behavioral and medication treatments for treating nicotine dependence have rarely been investigated in PLWHA. Methods: We present a review of studies examining the efficacy of smoking cessation interventions. Results and Conclusions:The literature reveals some limited evidence for the efficacy of behavioral interventions. However, the research literature on these interventions is sparse and the efficacy findings are mixed. Studies exploring the use of mobile technologies for reducing treatment barriers are becoming more prevalent. Few published trials have directly examined the efficacy of pharmacological smoking cessation interventions among PLWHA. Specific gaps in the treatment literature are discussed in detail, and a strategy is presented for developing a greater understanding of factors that contribute to the efficacy of smoking cessation among PLWHA. Implications: This paper provides the most comprehensive review to date on smoking cessation intervention research conducted with PLWHA. It also discusses specific gaps in the literature that should be a priority for future research.

show abstract

Section: Medication Treatmentsmentioning

confidence: 99%

Smoking Cessation for People Living With HIV/AIDS: A Literature Review and Synthesis

Ledgerwood

Yskes

2016

NICTOB

View full text Add to dashboard Cite

show abstract

“…The data on the efficacy and safety of pharmacotherapy for tobacco dependence in the setting of antiretroviral agents and in HIV-infected patients are currently limited[52, 32, 53]. A recent preliminary non-randomized 12-week study in which all participants received telephone counseling and either varenicline or nicotine replacement therapy found that varenicline was associated with a greater odds of abstinence compared with nicotine replacement therapy.…”

Section: Tobaccomentioning

confidence: 99%

Substance use in older HIV-infected patients

Edelman¹,

Tetrault²,

Fiellin³

2014

Current Opinion in HIV and AIDS

View full text Add to dashboard Cite

Purpose of the Review Substance use may persist throughout the life course and has a substantial impact on health outcomes globally. As HIV-infected individuals are disproportionately impacted by substance use and living longer, it is critical that providers and researchers alike understand the impact of substance use on older, HIV-infected patients and potential treatment options. To this end, we conducted a review of the literature focusing on the most commonly used substances to outline the epidemiology, health consequences, treatment options and latest research relevant to older, HIV-infected patients. Recent Findings Substance use impacts older, HIV-infected patients with regards to HIV-related and non-HIV related outcomes. Counseling strategies are available for marijuana and stimulant use disorders. Brief counseling is useful alongside medications for alcohol, tobacco and opioid use disorders. Many medications for alcohol, tobacco, and opioid use disorders are safe in the setting of antiretroviral therapy. Unfortunately, few interventions targeting substance use in older, HIV-infected patients have been developed and evaluated. Summary As older, HIV-infected patients continue to experience substance use and its related health consequences, there will be a growing need for the development of safe and effective interventions which address the complex needs of this population.

show abstract

“…Only two studies to date have reported AEs among HIVinfected individuals on varenicline. In one study of 18 participants, nausea was reported by fi ve individuals and sleep disturbances in six ; none had to discontinue medication due to AEs ( Tornero & Mafé, 2009 ). In another study of 36 participants, the most common AEs were nausea (33%) and abnormal dreams (31%); 17% had to discontinue varenicline due to an AE ( Cui et al, 2012 ).…”

Section: Nicotine and Tobacco Researchmentioning

confidence: 99%